- Home
- PETZ vs PMCB Comparison
PETZ vs PMCB Comparison
Compare PETZ & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETZ | PMCB |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 6.3M |
| IPO Year | 2017 | 2001 |
Fundamental Metrics
Financial Performance| Metric | PETZ | PMCB |
|---|---|---|
| Price | $1.35 | $0.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 388.8K | 281.5K |
| Earning Date | 04-20-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $0.33 |
| 52 Week High | $1.83 | $1.51 |
Technical Indicators
Market Signals| Indicator | PETZ | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 49.92 | N/A |
| Support Level | $1.01 | N/A |
| Resistance Level | $1.37 | N/A |
| Average True Range (ATR) | 0.14 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 14.81 | 0.00 |
Price Performance
Historical ComparisonAbout PETZ TDH Holdings Inc.
TDH Holdings Inc currently focus on commercial real estate management. The company has determined that it has only one operating segment which is commercial real estate leasing operations. The company has presence in China and United States of which majority of revenue comes from China.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.